Argos Therapeutics, Inc.
Records under this name other than patents Argos Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Argos Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,893,200 | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,040,303 | Apparatus for measuring volume of a fluid Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,030,080 | Systems and methods for processing samples in a closed container, and related devices Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,085,807 | Strain-independent amplification of pathogens and vaccines thereto Formerly held Term ended Term ended Oct 14, 2026 · USPTO record | Term ended | Term ended Oct 14, 2026 | USPTO record |
| US 10,022,731 | Centrifuge Vessels with a Center Mound and an Internal Elongate Tube Suitable for Live Cell Processing and Associated Systems and Methods Formerly held Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 9,970,068 | Primers and probes for the amplification and detection of HIV GAG, REV and NEF polynucleotides Formerly held Lapsed on the fee record Ended May 15, 2026 · USPTO record | Lapsed on the fee record | Ended May 15, 2026 | USPTO record |
| US 9,102,726 | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same Formerly held Term ended Term ended Mar 27, 2026 · USPTO record | Term ended | Term ended Mar 27, 2026 | USPTO record |
| US 8,672,879 | Devices, systems and related methods suitable for delivery of a liquid medicament stored at cryogenic temperatures Formerly held Lapsed on the fee record Ended Mar 18, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 18, 2026 | USPTO record |
| US 8,658,771 | Humanized Antibodies Against Human Interferon-Alpha Formerly held Lapsed on the fee record Ended Feb 25, 2026 · Medium confidence | Lapsed on the fee record | Ended Feb 25, 2026 | Medium confidence |
| US 11,248,209 | Mature Dendritic Cell Compositions and Methods for Culturing Same Formerly held Lapsed on the fee record Ended Feb 15, 2026 · High confidence | Lapsed on the fee record | Ended Feb 15, 2026 | High confidence |